Oseltamivir

Treatment of influenza Adults and adolescents (13 years and older): 75 mg twice daily for 5 days Pediatric patients 1 to 12 years of age: Based on weight twice daily for 5 days Pediatric patients 2 weeks to less than 1 year of age: 3mg/kg twice daily for 5 days Renally impaired adult patients (creatinine clearance >30 to 60 mL/min): Reduce to 30 mg twice daily for 5 days Renally impaired adult patients (creatinine clearance >10 to 30 mL/min): Reduce to 30 mg once daily for 5 days ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after every hemodialysis cycle.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Oseltamivir phosphate for oral suspension is contraindicated in patients with known serious hypersensitivity to oseltamivir or any component of the product. Severe allergic reactions have included anaphylaxis and serious skin reactions including toxic epidermal necrolysis, Stevens-Johnson Syndrome, and erythema multiforme. Patients with known serious hypersensitivity to oseltamivir or any of the components of oseltamivir phosphate for oral suspension

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Serious skin/hypersensitivity reactions such as Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme: Discontinue oseltamivir phosphate for oral suspension and initiate appropriate treatment if allergic-like reactions occur or are suspected. Neuropsychiatric events: Patients with influenza, including those receiving oseltamivir phosphate for oral suspension, particularly pediatric patients, may be at an increased risk of confusion or abnormal behavior early in their illness. Monitor for signs of abnormal behavior.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following serious adverse reactions are discussed below and elsewhere in the labeling: Serious skin and hypersensitivity reactions Neuropsychiatric events Most common adverse reactions (> 1% and more common than with placebo): Treatment studies – Nausea, vomiting, headache. Prophylaxis studies – Nausea, vomiting, headache, pain. To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc.

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

2 products from 1 maker in the NepalDoc medicine catalog use this generic:

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Store dry powder at 20º to 25ºC (68º to 77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). Preserved in well closed container. Store constituted oral suspension under refrigeration for up to 17 days at 2º to 8ºC (36º to 46ºF). Do not freeze.

Storage information from the U.S. FDA-approved label.